Ilana Meyer is a member of 麻豆传媒 & Lardner鈥檚 Health Care Practice Group. She began at 麻豆传媒 as a summer associate. While in law school, she worked as a Judicial Intern for Senior Judge Paul L. Friedman of the United States District Court for the District of Columbia. Most recently, Ilana interned in the Office of General Counsel for the Dana-Farber Cancer Institute working on regulatory and policy issues. 聽She also has experience within a multidisciplinary team, performing complex clinical ethics consultations.
Presentations and Publications
- Co-author, 鈥淢assachusetts: New Year, New Law 鈥 Governor Signs 鈥淎n Act enhancing the market review process鈥 (House Bill No. 5159),” Health Care Law Today (January 14, 2025)
- Co-author, 鈥淢assachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry,鈥 Health Care Law Today (August 5, 2024)
- Co-author, 鈥淐linical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use,鈥 Health Care Law Today (March 13, 2024)
麻豆传媒 Attorneys Contribute to American Health Law Association's Representing Physicians Handbook
麻豆传媒 attorneys Jana Kolarik, Claire Marblestone, Illana Meyer, Sheridan Organ, and Kate Pamperin contributed to the Fifth Edition of the American Health Law Association's (AHLA) Representing Physician's Handbook.
Massachusetts: New Year, New Law 鈥 Governor Signs 鈥淎n Act enhancing the market review process鈥 (House Bill No. 5159)
On January 8, 2025, Governor Maura Healey signed into law H.B. 5159, 鈥渁n Act enhancing the market review process.鈥
Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry
The Massachusetts legislative session officially closed on August 1, 2024 after an unusual half day extension.
What Does the End of Chevron Deference Mean for Federal Health Care Programs?
On June 28, 2024, the Supreme Court rejected the doctrine of Chevron deference in the closely watched case of Loper Bright Enterprises v. Raimondo.
Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use聽
In February 2024, the U.S. Food and Drug Administration published its finalized guidance concerning its investigational drug charging regulations.